A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes
Pediatric Diabetes, 05/09/2012
Lucchesi MBB et al. – The data suggest that mixing insulin lispro (IL) with insulin glargine (IG) immediately before the subcutaneous (SC) injection decreases IL serum peak concentration without affecting the glycemic profile after 12wk in this group with type 1 diabetes mellitus.
The IL serum profiles were evaluated in 10 individuals with type 1 diabetes [age 21.9±3.8yr; diabetes duration 13.4±4.9yr; body mass index 25.1±3.2 kg/m2; hemoglobin A1c (HbA1c) 8.3±0.8%] during a mixed meal test (MMT) using IL and IG as separate (baseline) and mixed injection.
The glycemic variability by continuous glucose monitoring system (CGMS) and the long-term diabetes control with HbA1c were also evaluated at baseline and after 12wk mixing the two insulins.
The mixture of IL with IG decreased IL maximum serum concentration (CmaxIL) (29.4±5.1µU/mL vs. 13.7±4.2µU/mL; p=0.03) without changing the time to reach the Cmax (TmaxIL), the IL area under the curve (AUCIL0-240), and the glucose dynamics during the MMT.
The glucose variability and the HbA1c were equivalent to baseline after 12wk mixing both insulins.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.